Clinical trials: RRMM
Multiple Myeloma
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
This is a single-arm that includes two experimental arms,Selinexor(ATG-010) in Combination with Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients.To evaluate efficacy and safety of ATG-010 in combination with…
- Trial name
- NCT04877275
- Testing
- Selinexor (80mg/d), Selinexor (100mg/d), Pegylated liposomal doxorubicin
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Chunyan Sun, MD
Relapsed/Refractory Multiple Myeloma
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination…
- Trial name
- NCT06160609
- Testing
- Belantamab Mafodotin, GSK3174998
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Multiple myeloma (MM) is an incurable disease characterized by the growth of monoclonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease state of etentamig in adult…
- Trial name
- NCT05286229
- Testing
- Etentamig
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- AbbVie
Relapsed/Refractory Multiple Myeloma
Cevostamab Following CAR T Cell Therapy for RRMM
This is a Phase 2, open-label, single-arm, single stage, single-institution study, with an initial safety run-in period. Potential participants with relapsed/refractory myeloma who are undergoing standard of care…
- Trial name
- NCT05801939
- Testing
- Cevostamab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the percentage of participants with a response of very good partial response (VGPR) or better to IDd treatment.
- Trial name
- NCT03439293
- Testing
- Ixazomib, Daratumumab, Dexamethasone
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 61 people
- Sponsor
- Takeda
Myeloma Multiple
Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Belantamab Mafodotin is the first antibody conjugate targeting B-cell maturation antigen (BCMA) in relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT05887206
- Testing
- Collection of datas
- Where
- 10 sites in France
- Volunteers
- 43 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort…
- Trial name
- NCT07217184
- Testing
- Belantamab mafodotin, Isatuximab
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents.
- Trial name
- ANCHOR (NCT03481556)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib
- Where
- 16 sites in United States, Czechia and 2 more
- Volunteers
- 56 people
- Sponsor
- Oncopeptides AB
Phase 2, Radiotherapy-Induced Immune Priming
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
- Conditions
- Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM)
- Trial name
- NCT07382739
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to see if the study drug, called Vactosertib, is safe and determine what the best dose is to treat future patients when given in combination with pomalidomide (POM).
- Trial name
- NCT03143985
- Testing
- Vactosertib, Pomalidomide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Koen van Besien
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.
- Trial name
- KMM-KCd (NCT05909826)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Volunteers
- 49 people
- Sponsor
- Dong-A University Hospital
Multiple Myeloma (MM), CART Therapy
Neurocognitive Trajectories After BCMA CAR-T
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).
- Conditions
- Multiple Myeloma (MM), CART Therapy, Refractory Multiple Myeloma (RRMM)
- Trial name
- CAR-T Cog (NCT07740317)
- Testing
- Standardized neurocognitive testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
This phase I trial studies the side effects and best dose of selvigaltin when given together with standard of care treatment (daratumumab-hyaluronidase, carfilzomib, dexamethasone) in treating patients with multiple myeloma that…
- Trial name
- NCT07082270
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Relapsed Refractory Multiple Myeloma (RRMM)
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
This is an open-label, single arm, multicenter study to evaluate the efficacy of letermovir in the prevention of clinically significant CMV infection in adult, CMV-seropositive relapsed/refractory MM patients undergoing BsAbs…
- Trial name
- OPTIMUS-EL (NCT06920251)
- Testing
- Letermovir
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This study is a single-center, open-label, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.
- Trial name
- NCT05759793
- Testing
- CAR-GPRC5D
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Multiple Myeloma, Relapse
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to…
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging
- Trial name
- NCT05911321
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
This feasibility trial studies the efficacy of administering iberdomide (CC-220) as a priming agent prior to leukapheresis in patients with relapsed/refractory multiple myeloma (RRMM) who are already planned for standard-of-care…
- Trial name
- NCT07727668
- Testing
- Iberdomide, CAR-T Leukapheresis, CAR-T Infusion
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Shambavi Richard
Multiple Myeloma (MM)
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT07280013
- Testing
- Cemsidomide, Elranatamab
- Where
- 19 sites in United States
- Volunteers
- 60 people
- Sponsor
- C4 Therapeutics, Inc.
Multiple Myeloma
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
There is a high unmet medical need for an anti-myeloma therapy for RRMM patients previously treated with Lenalidomide and Bortezomib, due to poor prognosis.
- Trial name
- NCT02555839
- Testing
- Pomalidomide, Dexamethasone, Bortezomib
- Where
- 13 sites in Austria
- Volunteers
- 127 people
- Sponsor
- Celgene